Alprolix Approval History
- FDA approved: Yes (First approved March 28th, 2014)
- Brand name: Alprolix
- Generic name: coagulation factor IX (recombinant)
- Company: Biogen
- Treatment for: Hemophilia B
Alprolix (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.
Development History and FDA Approval Process for Alprolix
|Mar 28, 2014||FDA Approves Alprolix (recombinant coagulation factor IX) for patients with Hemophilia B|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.